Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-22
2008-01-22
Weber, Jon (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S054000, C514S060000, C514S777000, C514S944000, C530S354000, C530S356000, C530S380000, C530S402000, C424S078020, C424S078060, C424S478000, C435S810000
Reexamination Certificate
active
07320962
ABSTRACT:
Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.
REFERENCES:
patent: 4265233 (1981-05-01), Sugitachi et al.
patent: 4291013 (1981-09-01), Wahlig et al.
patent: 4300494 (1981-11-01), Graiff et al.
patent: 4347234 (1982-08-01), Wahling et al.
patent: 4424208 (1984-01-01), Wallace et al.
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 4655211 (1987-04-01), Sakamoto et al.
patent: 4803075 (1989-02-01), Wallace et al.
patent: 4891359 (1990-01-01), Saferstein et al.
patent: 4925677 (1990-05-01), Feijen
patent: 4946870 (1990-08-01), Partain, II et al.
patent: 5165938 (1992-11-01), Knighton
patent: 5178883 (1993-01-01), Knighton
patent: 5196185 (1993-03-01), Silver et al.
patent: 5204382 (1993-04-01), Wallace et al.
patent: 5292362 (1994-03-01), Bass et al.
patent: 5352715 (1994-10-01), Wallace et al.
patent: 5356614 (1994-10-01), Sharma
patent: 5384333 (1995-01-01), Davis et al.
patent: 5385606 (1995-01-01), Kowanko
patent: 5399361 (1995-03-01), Song et al.
patent: 5428024 (1995-06-01), Chu et al.
patent: 5516532 (1996-05-01), Atala et al.
patent: 5595735 (1997-01-01), Saferstein et al.
patent: 5648506 (1997-07-01), Desai et al.
patent: 5672336 (1997-09-01), Sharma
patent: 6066325 (2000-05-01), Wallace et al.
patent: 6110484 (2000-08-01), Sierra
patent: 6277394 (2001-08-01), Sierra
patent: 6706690 (2004-03-01), Reich et al.
patent: WO96/06883 (1996-03-01), None
patent: WO96/10374 (1996-04-01), None
patent: WO96/10428 (1996-04-01), None
patent: WO96/39159 (1996-12-01), None
patent: WO98/08550 (1998-03-01), None
Ansell et al., “Gelfoam and autologous clot embolization: Effect on coagulation”Invest. Radiol.(1978) 13:115-120.
Barton et al., “Fibrin glue as a biologic vascular patch—a comparative study” (abstract posted at http://www.ncbi.nlm.nih.gov/ on Jan. 3, 2001 from)J. Surg. Res.(1986) 40(5):510-513.
Bruck, S.D., Ed., “Controlled Drug Delivery”, CRC Press, Boca Raton, FL (1983) (title page and table of contents).
Cantor et al., “Gelfoam and thrombin in gastrointestinal bleeding: An experimental study” pp. 890-893.
Cantor et al., “Gelfoam and thrombin in treatment of massive gastroduodenal hemorrhage: A preliminary report”Am. J. Surg.(1950) pp. 883-887.
Cantor et al., “Gelfoam and thrombin in treatment of massive upper gastrointestinal hemorrhage”Am. J. Surg.(1951) pp. 230-235.
Chuang et al. “Sheath needle for liver biopsy in high-risk patients”Radiology(1988) 166:261-262.
Collins et al., “Enemata of gelfoam-milk suspension combined with thrombin solution to control massive hemorrhage following anorectal surgery”Am. J. Proctol.(1951) 2:60-63.
Edgerton et al., “Vascular hamartomas and hemangiomas: Classification and treatment”Southern Med. J.(1982) 75(12):1541-1547.
Heller et al., “Release of norethindrone from poly(ortho esters)” Polymer Engineering Scien. (1981) 21(11):727-731.
Hotz et al. “Collagen and fibrin as biologic binders for granular hydroxyapatite” (abstract posted at http://www.ncbi.nlm.nih.gov/ on Jan. 3, 2001 from)Dtsch. Z. Mund. Kiefer Gesichstshir.(1989) 13(4):296-300.
Jeong et al., “Biodegradable block copolymers as injectable drug-delivery systems” Nature (1997) 388:860-862.
Krill et al., “Topical thrombin and powdered Gelfoam: An efficient hemostatic treatment for surgery”J. Tenn. Dent. Assoc.(1986) 66(2):26-27.
Langer et al., “Chemical and physical structure of polymers as carriers for controlled release of bioactive agents: A review” Rev. Macro. Chem. Phys. (1983) C23(1):61-126.
Leong et al., “Polyanhydrides for controlled release of bioactive agents” Biomaterials (1986) 7:364-371.
Leong et al., “Polymeric controlled drug delivery” Adv. Drug Delivery Review (1987) 1:199-233.
Maok, “Hemostatic Agents” (1991)Today's O.R. Nurse, pp. 6-10.
Masal et al., “Synthesis of polyurethanes and investigation of other hydrolytic stability” Journal of Polymer Science, Polymer Symposium (1979) 66:259-268.
McClure et al., “Massive gastroduodenal hemorhage: Treatment with powered Gelfoam and buffered thrombin solution”Surg.(1952) 32:630-637.
Pitt et al., “Biodegradable drug delivery systems based on aliphatic polyesters: Application to contraceptives and narcotic antagonists” Controlled Release of Bioactive Materials, Baker, R., Ed., Academic Press, New York (1980) pp. 19-43.
Riley et al., “Percutaneous liver biopsy with plugging of needle track: A safe method for use in patients with impaired coagulation”Lancet(Aug. 25, 1984) pp. 436.
Sidman et al., “Biodegradable, implantable sustained release systems based on glutamic acid copolymers” Journal of Membrane Science (1979) 7:227-291.
Sugitachi et al. “Preoperative transcatheter arterial chemo-embolization for locally advanced breast cancer. Application for new thrombotic materials”Japan J. Surg.(1983) 13(5):456-458.
Sugitachi et al., “A newly devised chemo-embolic agent, G.T. XIII-ADM.” (English abstract posted at http://www.ncbi.nlm.nih.gov/ on Jan. 3, 2001 from)Gan. To. Kagaku Ryoho.(1985) 12(10) 1942-1943.
Sugitachi et al., “Locoregional therapy in patients with malignant pleural effusion—two different types of BAC therapy” (English abstract posted at http://www.ncbi.nlm.nih.gov/ on Jan. 3, 2001 from)Gan. To. Kagaku Ryoho.(1992) 19(10):1640-1643.
Tobin et al., “Plugged liver biopsy in patients with impaired coagulation” (1989)Digestive Diseases and Science(1989) 34(1):13-15.
Tucker et al.,Absorbable Gelatin(Gelfoam)Sponge, Charles C. Thomas, Publisher, Springfield, Illinois, 3-125.
Vander Salm et al., “Reduction of sternal infection by application of topical vancomycin”J. Thorac. Surg.(1989) 98:618-622.
Yuki et al., “Effects of endoscopic variceal sclerotherapy using GT XIII on blood coagulation tests and the renal kallikrein-kinin system” (English abstract posted as http://www.ncbi.nlm.nih.gov/ on Jan. 2, 2001 from)Gastroentrol. Japan(1990) 25(5):561-567.
Zins et al., “US-guided percutaneous liver biopsy with plugging of the needle track: A prospective study in 72 high-risk patients”Radiology(1992) 184(3):841-843.
Osawa A. Edward
Reich Cary J.
Tran Helen
Baxter Healthcare S.A.
Baxter International Inc.
Mohamed Abdel A.
Townsend and Townsend / and Crew LLP
Weber Jon
LandOfFree
Hemoactive compositions and methods for their manufacture... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hemoactive compositions and methods for their manufacture..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hemoactive compositions and methods for their manufacture... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2764908